- Home
- IGMS vs THCH Comparison
IGMS vs THCH Comparison
Compare IGMS & THCH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IGMS
- THCH
- Stock Information
- Founded
- IGMS 1993
- THCH 2018
- Country
- IGMS United States
- THCH China
- Employees
- IGMS N/A
- THCH N/A
- Industry
- IGMS Biotechnology: Pharmaceutical Preparations
- THCH Blank Checks
- Sector
- IGMS Health Care
- THCH Finance
- Exchange
- IGMS Nasdaq
- THCH Nasdaq
- Market Cap
- IGMS 82.1M
- THCH 73.0M
- IPO Year
- IGMS 2019
- THCH N/A
- Fundamental
- Price
- IGMS $1.22
- THCH $2.72
- Analyst Decision
- IGMS Hold
- THCH
- Analyst Count
- IGMS 8
- THCH 0
- Target Price
- IGMS $6.14
- THCH N/A
- AVG Volume (30 Days)
- IGMS 167.6K
- THCH 19.8K
- Earning Date
- IGMS 05-07-2025
- THCH 04-15-2025
- Dividend Yield
- IGMS N/A
- THCH N/A
- EPS Growth
- IGMS N/A
- THCH N/A
- EPS
- IGMS N/A
- THCH N/A
- Revenue
- IGMS $2,679,000.00
- THCH $190,593,087.00
- Revenue This Year
- IGMS $121.76
- THCH N/A
- Revenue Next Year
- IGMS $46.83
- THCH N/A
- P/E Ratio
- IGMS N/A
- THCH N/A
- Revenue Growth
- IGMS 25.77
- THCH N/A
- 52 Week Low
- IGMS $0.92
- THCH $2.15
- 52 Week High
- IGMS $22.50
- THCH $7.20
- Technical
- Relative Strength Index (RSI)
- IGMS 47.65
- THCH 49.66
- Support Level
- IGMS $1.16
- THCH $2.15
- Resistance Level
- IGMS $1.31
- THCH $2.38
- Average True Range (ATR)
- IGMS 0.12
- THCH 0.21
- MACD
- IGMS 0.03
- THCH 0.02
- Stochastic Oscillator
- IGMS 76.92
- THCH 59.94
About IGMS IGM Biosciences Inc.
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.
About THCH TH International Limited Ordinary shares
TH International Ltd is the parent company of the franchise of Tim Hortons coffee shops and has the rights to operate Tim Hortons coffee shops in mainland China, Hong Kong, and Macau. Through the Tim Hortons brand, the firm offers freshly brewed coffee, tea, and other beverages, bakery & sides, and sandwiches. It is also the operator and developer of Popeyes brand in Mainland China. The firm has two reportable segments; Tim Hortons which generates key revenue, and Popeyes. The company's revenue is derived from its operations in the PRC.